Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Reply to: Does lymphovascular invasion really associate with decreased overall survival for patients with resected cholangiocarcinoma?

Bednarsch J, Neumann UP, Lurje G.

Eur J Surg Oncol. 2019 May 31. pii: S0748-7983(19)30490-1. doi: 10.1016/j.ejso.2019.05.030. [Epub ahead of print] No abstract available.

PMID:
31178299
2.

The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.

Lurje G, Bednarsch J, Czigany Z, Lurje I, Schlebusch IK, Boecker J, Meister FA, Tacke F, Roderburg C, Den Dulk M, Gaisa NT, Bruners P, Neumann UP.

Eur J Surg Oncol. 2019 Apr 25. pii: S0748-7983(19)30411-1. doi: 10.1016/j.ejso.2019.04.019. [Epub ahead of print]

PMID:
31053477
3.

Median Arcuate Ligament Compression in Orthotopic Liver Transplantation: Results from a Single-Center Analysis and a European Survey Study.

Czigany Z, Boecker J, Morales Santana DA, Bednarsch J, Meister FA, Amygdalos I, Isfort P, Liebl M, Neumann UP, Lurje G.

J Clin Med. 2019 Apr 23;8(4). pii: E550. doi: 10.3390/jcm8040550.

4.

Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach.

Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G.

Int J Mol Sci. 2019 Mar 22;20(6). pii: E1465. doi: 10.3390/ijms20061465. Review.

5.

Potential value and limitations of different clinical scoring systems in the assessment of short- and long-term outcome following orthotopic liver transplantation.

Boecker J, Czigany Z, Bednarsch J, Amygdalos I, Meister F, Santana DAM, Liu WJ, Strnad P, Neumann UP, Lurje G.

PLoS One. 2019 Mar 21;14(3):e0214221. doi: 10.1371/journal.pone.0214221. eCollection 2019.

6.

Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation.

Schmitz S, Lurje G, Ulmer F, Andert A, Bruners P, Schulze-Hagen M, Neumann U, Schoening W.

Hepatobiliary Pancreat Dis Int. 2019 Jun;18(3):228-236. doi: 10.1016/j.hbpd.2019.01.004. Epub 2019 Jan 21.

PMID:
30718181
7.

Systematic Review on Characteristics and Reporting Quality of Animal Studies in Liver Regeneration Triggered by Portal Vein Occlusion and Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy: Adherence to the ARRIVE Guidelines.

Tihanyi DK, Szijarto A, Fülöp A, Denecke B, Lurje G, Neumann UP, Czigany Z, Tolba R.

J Surg Res. 2019 Mar;235:578-590. doi: 10.1016/j.jss.2018.10.038. Epub 2018 Dec 5. Review.

PMID:
30691845
8.

Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma.

Loosen SH, Lurje G, Wiltberger G, Vucur M, Koch A, Kather JN, Paffenholz P, Tacke F, Ulmer FT, Trautwein C, Luedde T, Neumann UP, Roderburg C.

PLoS One. 2019 Jan 17;14(1):e0210944. doi: 10.1371/journal.pone.0210944. eCollection 2019.

9.

The Role of Macrophage Migration Inhibitory Factor in Remote Ischemic Conditioning Induced Hepatoprotection in A Rodent Model of Liver Transplantation.

Emontzpohl C, Stoppe C, Theißen A, Beckers C, Neumann UP, Lurje G, Ju C, Bernhagen J, Tolba RH, Czigany Z.

Shock. 2018 Dec 21. doi: 10.1097/SHK.0000000000001307. [Epub ahead of print]

PMID:
30601408
10.

Heterozygosity for the Alpha-1-Antitrypsin Z Allele in Cirrhosis Is Associated With More Advanced Disease.

Meister F, Lurje G, Neumann UP, Trautwein C, Strnad P.

Liver Transpl. 2019 Feb;25(2):342-343. doi: 10.1002/lt.25393. No abstract available.

PMID:
30525305
11.

Performance validation of the ALPPS risk model.

Linecker M, Kuemmerli C, Kambakamba P, Schlegel A, Muiesan P, Capobianco I, Nadalin S, Torres OJ, Mehrabi A, Stavrou GA, Oldhafer KJ, Lurje G, Balci D, Lang H, Robles-Campos R, Hernandez-Alejandro R, Malago M, De Santibanes E, Clavien PA, Petrowsky H.

HPB (Oxford). 2019 Jun;21(6):711-721. doi: 10.1016/j.hpb.2018.10.003. Epub 2018 Nov 24.

PMID:
30477898
12.

Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent.

Lurje G, Bednarsch J, Czigany Z, Amygdalos I, Meister F, Schöning W, Ulmer TF, Foerster M, Dejong C, Neumann UP.

Langenbecks Arch Surg. 2018 Nov;403(7):851-861. doi: 10.1007/s00423-018-1715-9. Epub 2018 Sep 28.

PMID:
30267147
13.

[Intrahepatic cholangiocarcinoma - current perspectives and treatment algorithm].

Lurje G, Bednarsch J, Roderburg C, Trautwein C, Neumann UP.

Chirurg. 2018 Nov;89(11):858-864. doi: 10.1007/s00104-018-0718-y. Review. German.

PMID:
30182267
14.

Machine perfusion for liver transplantation in the era of marginal organs-New kids on the block.

Czigany Z, Lurje I, Tolba RH, Neumann UP, Tacke F, Lurje G.

Liver Int. 2019 Feb;39(2):228-249. doi: 10.1111/liv.13946. Epub 2018 Sep 29. Review.

PMID:
30129192
15.

Technical Aspects of Orthotopic Liver Transplantation-a Survey-Based Study Within the Eurotransplant, Swisstransplant, Scandiatransplant, and British Transplantation Society Networks.

Czigany Z, Scherer MN, Pratschke J, Guba M, Nadalin S, Mehrabi A, Berlakovich G, Rogiers X, Pirenne J, Lerut J, Mathe Z, Dutkowski P, Ericzon BG, Malagó M, Heaton N, Schöning W, Bednarsch J, Neumann UP, Lurje G.

J Gastrointest Surg. 2019 Mar;23(3):529-537. doi: 10.1007/s11605-018-3915-6. Epub 2018 Aug 10.

PMID:
30097968
16.

Limb remote ischemic conditioning of the recipient protects the liver in a rat model of arterialized orthotopic liver transplantation.

Czigany Z, Bleilevens C, Beckers C, Stoppe C, Möhring M, Fülöp A, Szijarto A, Lurje G, Neumann UP, Tolba RH.

PLoS One. 2018 Apr 4;13(4):e0195507. doi: 10.1371/journal.pone.0195507. eCollection 2018.

17.

CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma.

Loosen SH, Roderburg C, Kauertz KL, Koch A, Vucur M, Schneider AT, Binnebösel M, Ulmer TF, Lurje G, Schoening W, Tacke F, Trautwein C, Longerich T, Dejong CH, Neumann UP, Luedde T.

Sci Rep. 2017 Dec 5;7(1):16975. doi: 10.1038/s41598-017-17175-7.

18.

Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD).

Czigany Z, Schöning W, Ulmer TF, Bednarsch J, Amygdalos I, Cramer T, Rogiers X, Popescu I, Botea F, Froněk J, Kroy D, Koch A, Tacke F, Trautwein C, Tolba RH, Hein M, Koek GH, Dejong CHC, Neumann UP, Lurje G.

BMJ Open. 2017 Oct 10;7(10):e017558. doi: 10.1136/bmjopen-2017-017558.

19.

Comparative study of the effects of terlipressin versus splenectomy on liver regeneration after partial hepatectomy in rats.

Ulmer TF, Weiland A, Lurje G, Klink C, Andert A, Alizai H, Heidenhain C, Neumann U.

Hepatobiliary Pancreat Dis Int. 2017 Oct 15;16(5):506-511. doi: 10.1016/S1499-3872(17)60036-5.

PMID:
28992883
20.

Risk Adjustment in ALPPS Is Associated With a Dramatic Decrease in Early Mortality and Morbidity.

Linecker M, Björnsson B, Stavrou GA, Oldhafer KJ, Lurje G, Neumann U, Adam R, Pruvot FR, Topp SA, Li J, Capobianco I, Nadalin S, Machado MA, Voskanyan S, Balci D, Hernandez-Alejandro R, Alvarez FA, De Santibañes E, Robles-Campos R, Malagó M, de Oliveira ML, Lesurtel M, Clavien PA, Petrowsky H.

Ann Surg. 2017 Nov;266(5):779-786. doi: 10.1097/SLA.0000000000002446.

21.

Rectal foreign body insertion as a rare cause of persistent lumbosacral plexus injury.

Meister FA, Amygdalos I, Neumann UP, Lurje G.

Ann R Coll Surg Engl. 2017 Jul;99(6):e191-e192. doi: 10.1308/rcsann.2017.0109.

22.

The ALPPS Risk Score: Avoiding Futile Use of ALPPS.

Linecker M, Stavrou GA, Oldhafer KJ, Jenner RM, Seifert B, Lurje G, Bednarsch J, Neumann U, Capobianco I, Nadalin S, Robles-Campos R, de Santibañes E, Malagó M, Lesurtel M, Clavien PA, Petrowsky H.

Ann Surg. 2016 Nov;264(5):763-771.

23.

Cosmesis and Body Image in Patients Undergoing Single-port Versus Conventional Laparoscopic Cholecystectomy: A Multicenter Double-blinded Randomized Controlled Trial (SPOCC-trial).

Lurje G, Raptis DA, Steinemann DC, Amygdalos I, Kambakamba P, Petrowsky H, Lesurtel M, Zehnder A, Wyss R, Clavien PA, Breitenstein S.

Ann Surg. 2015 Nov;262(5):728-34; discussion 734-5. doi: 10.1097/SLA.0000000000001474.

24.

An undigested cherry tomato as a rare cause of small bowel obstruction.

Mortezavi A, Schneider PM, Lurje G.

Ann R Coll Surg Engl. 2015 Jul;97(5):e83-4. doi: 10.1308/rcsann.2015.0004.

25.

Monosegment ALPPS hepatectomy: extending resectability by rapid hypertrophy.

Schadde E, Malagó M, Hernandez-Alejandro R, Li J, Abdalla E, Ardiles V, Lurje G, Vyas S, Machado MA, de Santibañes E.

Surgery. 2015 Apr;157(4):676-89. doi: 10.1016/j.surg.2014.11.015. Epub 2015 Feb 21.

PMID:
25712199
26.

Multimodal treatment strategies in patients undergoing surgery for hepatocellular carcinoma.

Lurje G, Lesurtel M, Clavien PA.

Dig Dis. 2013;31(1):112-7. doi: 10.1159/000347205. Epub 2013 Jun 17. Review.

27.

Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity.

Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ.

J Gastrointest Oncol. 2011 Jun;2(2):77-84. doi: 10.3978/j.issn.2078-6891.2010.025.

28.

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.

Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2013 Apr;13(2):173-80. doi: 10.1038/tpj.2011.61. Epub 2012 Jan 10.

29.

Cosmesis and body image after single-port laparoscopic or conventional laparoscopic cholecystectomy: a multicenter double blinded randomised controlled trial (SPOCC-trial).

Steinemann DC, Raptis DA, Lurje G, Oberkofler CE, Wyss R, Zehnder A, Lesurtel M, Vonlanthen R, Clavien PA, Breitenstein S.

BMC Surg. 2011 Sep 12;11:24. doi: 10.1186/1471-2482-11-24.

30.

Evaluation of quality indicators following implementation of total mesorectal excision in primarily resected rectal cancer changed future management.

Schneider PM, Vallbohmer D, Ploenes Y, Lurje G, Metzger R, Ling FC, Brabender J, Drebber U, Hoelscher AH.

Int J Colorectal Dis. 2011 Jul;26(7):903-9. doi: 10.1007/s00384-011-1155-2. Epub 2011 Feb 22.

31.

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F, Lurje G, Labonte M, Wilson P, Sherrod A, Ladner RD, Lenz HJ.

Pharmacogenomics. 2011 Jan;12(1):27-39. doi: 10.2217/pgs.10.163.

32.

Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma.

Winder T, Ning Y, Yang D, Zhang W, Power DG, Bohanes P, Gerger A, Wilson PM, Lurje G, Tang LH, Shah M, Lenz HJ.

Int J Cancer. 2011 Sep 1;129(5):1096-104. doi: 10.1002/ijc.25787. Epub 2011 Feb 11.

33.

Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).

Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, Ning Y, Bohanes P, Gerger A, Winder T, Hollywood E, Danenberg KD, Saltz L, Lenz HJ.

Anticancer Res. 2010 Oct;30(10):4209-17.

PMID:
21036743
34.

Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction.

Lurje G, Lenz HJ.

Recent Results Cancer Res. 2010;182:179-91. doi: 10.1007/978-3-540-70579-6_15. Review.

PMID:
20676881
35.

Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.

Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ.

Int J Cancer. 2011 May 1;128(9):2038-49. doi: 10.1002/ijc.25562.

36.

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.

Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.

Ann Oncol. 2011 Jan;22(1):104-9. doi: 10.1093/annonc/mdq315. Epub 2010 Jul 5.

37.

EGFR signaling and drug discovery.

Lurje G, Lenz HJ.

Oncology. 2009;77(6):400-10. doi: 10.1159/000279388. Epub 2010 Feb 2. Review.

PMID:
20130423
38.

Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus.

Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Ayazi S, Winder T, Ning Y, Yang D, Klipfel NE, Chandrasoma P, Hagen JA, DeMeester SR, DeMeester TR, Lenz HJ.

Ann Surg. 2010 May;251(5):857-64. doi: 10.1097/SLA.0b013e3181c97fcf.

PMID:
20101173
39.

Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications.

Lurje G, Schiesser M, Claudius A, Schneider PM.

J Oncol. 2010;2010:392652. doi: 10.1155/2010/392652. Epub 2009 Nov 5.

40.

Gender disparities in metastatic colorectal cancer survival.

Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ.

Clin Cancer Res. 2009 Oct 15;15(20):6391-7. doi: 10.1158/1078-0432.CCR-09-0877. Epub 2009 Sep 29.

41.

Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma.

Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, Zhang W, Ning Y, Manegold PC, El-Khoueiry A, Iqbal S, Tang LH, Shah MA, Lenz HJ.

Ann Oncol. 2010 Jan;21(1):78-86. doi: 10.1093/annonc/mdp280. Epub 2009 Jul 21.

42.

ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer.

Warnecke-Eberz U, Vallböhmer D, Alakus H, Kütting F, Lurje G, Bollschweiler E, Wienand-Dorweiler A, Drebber U, Hölscher AH, Metzger R.

J Gastrointest Surg. 2009 Aug;13(8):1411-21. doi: 10.1007/s11605-009-0881-z. Epub 2009 May 7.

PMID:
19421825
43.

The role of the homeobox genes BFT and CDX2 in the pathogenesis of non-small cell lung cancer.

Grimminger P, Ling FC, Neiss S, Vallböhmer D, Lurje G, Schneider PM, Hölscher AH, Metzger R, Brabender J.

Anticancer Res. 2009 Apr;29(4):1281-6.

44.

Thymidylate synthase gene variations: predictive and prognostic markers.

Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ.

Mol Cancer Ther. 2009 May;8(5):1000-7. doi: 10.1158/1535-7163.MCT-08-0219. Epub 2009 Apr 21. Review.

45.

Endoscopic therapy for esophageal perforation or anastomotic leak with a self-expandable metallic stent.

Leers JM, Vivaldi C, Schäfer H, Bludau M, Brabender J, Lurje G, Herbold T, Hölscher AH, Metzger R.

Surg Endosc. 2009 Oct;23(10):2258-62. doi: 10.1007/s00464-008-0302-5. Epub 2009 Jan 28.

PMID:
19184216
46.

Dihydropyrimidine dehydrogenase mRNA expression in peripheral blood of rectal cancer patients is significantly associated with residual tumor and distant metastases following resection.

Hoffmann AC, Brabender J, Metzger R, Ling F, Warnecke-Eberz U, Lurje G, Hoelscher AH, Schneider PM, Vallböhmer D.

J Surg Oncol. 2009 Apr 1;99(5):296-301. doi: 10.1002/jso.21233.

PMID:
19180589
47.

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.

Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR.

Cancer Chemother Pharmacol. 2009 Sep;64(4):777-83. doi: 10.1007/s00280-009-0927-7. Epub 2009 Jan 24.

PMID:
19169683
48.

Pharmacogenomics and -genetics in colorectal cancer.

Pohl A, Lurje G, Manegold PC, Lenz HJ.

Adv Drug Deliv Rev. 2009 May 20;61(5):375-80. doi: 10.1016/j.addr.2008.10.002. Epub 2008 Dec 3. Review.

PMID:
19100300
49.

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.

Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.

Clin Cancer Res. 2008 Dec 1;14(23):7884-95. doi: 10.1158/1078-0432.CCR-07-5165.

50.

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.

Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ.

Clin Cancer Res. 2008 Nov 15;14(22):7554-63. doi: 10.1158/1078-0432.CCR-08-0351.

Supplemental Content

Support Center